197 related articles for article (PubMed ID: 8487245)
1. Preclinical and clinical pharmacology of carvedilol.
Ruffolo RR; Boyle DA; Venuti RP; Lukas MA
J Hum Hypertens; 1993 Feb; 7 Suppl 1():S2-15. PubMed ID: 8487245
[TBL] [Abstract][Full Text] [Related]
2. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity.
Feuerstein GZ; Yue TL; Cheng HY; Ruffolo RR
J Hypertens Suppl; 1993 Jun; 11(4):S41-8. PubMed ID: 8104241
[TBL] [Abstract][Full Text] [Related]
3. A new molecule with vasodilating and beta-adrenoceptor blocking properties.
Abshagen U
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S23-32. PubMed ID: 2454364
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol.
Bril A; Slivjak M; DiMartino MJ; Feuerstein GZ; Linee P; Poyser RH; Ruffolo RR; Smith EF
Cardiovasc Res; 1992 May; 26(5):518-25. PubMed ID: 1359930
[TBL] [Abstract][Full Text] [Related]
5. The pharmacology of carvedilol.
Ruffolo RR; Gellai M; Hieble JP; Willette RN; Nichols AJ
Eur J Clin Pharmacol; 1990; 38 Suppl 2():S82-8. PubMed ID: 1974511
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
Ruffolo RR; Feuerstein GZ
Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():247-56. PubMed ID: 9211017
[TBL] [Abstract][Full Text] [Related]
7. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection.
Feuerstein GZ; Ruffolo RR
Eur Heart J; 1995 Jul; 16 Suppl F():38-42. PubMed ID: 8521883
[TBL] [Abstract][Full Text] [Related]
8. Myocardial protection with carvedilol.
Feuerstein GZ; Hamburger SA; Smith EF; Bril A; Ruffolo RR
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S138-41. PubMed ID: 1378142
[TBL] [Abstract][Full Text] [Related]
9. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.
Feuerstein GZ; Ruffolo RR
Eur Heart J; 1996 Apr; 17 Suppl B():24-9. PubMed ID: 8733068
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients.
Deetjen A; Heidland A; Pangerl A; Meyer-Sabellek W; Schaefer RM
Clin Nephrol; 1995 Jan; 43(1):47-52. PubMed ID: 7697935
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
[TBL] [Abstract][Full Text] [Related]
12. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol.
Nichols AJ; Gellai M; Ruffolo RR
Fundam Clin Pharmacol; 1991; 5(1):25-38. PubMed ID: 1712335
[TBL] [Abstract][Full Text] [Related]
13. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
McTavish D; Campoli-Richards D; Sorkin EM
Drugs; 1993 Feb; 45(2):232-58. PubMed ID: 7681374
[TBL] [Abstract][Full Text] [Related]
14. [Carvedilol].
Antepohl W; Herzig S; Böhm M
Dtsch Med Wochenschr; 1997 Jun; 122(25-26):833-4. PubMed ID: 9244672
[No Abstract] [Full Text] [Related]
15. Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension.
Di Verniero CA; Bertera F; Buontempo F; Bernabeu E; Chiappetta D; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharm Pharmacol; 2010 Jul; 62(7):890-900. PubMed ID: 20636877
[TBL] [Abstract][Full Text] [Related]
16. Vasodilatory action of carvedilol.
Sponer G; Strein K; Bartsch W; Müller-Beckmann B
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S5-11. PubMed ID: 1378150
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotective potential of carvedilol.
Ruffolo RR; Bril A; Feuerstein GZ
Cardiology; 1993; 82 Suppl 3():24-8. PubMed ID: 8106160
[TBL] [Abstract][Full Text] [Related]
18. Carvedilol in the treatment of hypertension--a review of the clinical data base.
Hansson L; Himmelmann A
Scand Cardiovasc J Suppl; 1998; 47():67-80. PubMed ID: 9540136
[TBL] [Abstract][Full Text] [Related]
19. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats.
Barone FC; Nelson AH; Ohlstein EH; Willette RN; Sealey JE; Laragh JH; Campbell WG; Feuerstein GZ
J Pharmacol Exp Ther; 1996 Nov; 279(2):948-55. PubMed ID: 8930204
[TBL] [Abstract][Full Text] [Related]
20. Role of carvedilol controlled-release in cardiovascular disease.
Fonarow GC
Expert Rev Cardiovasc Ther; 2009 May; 7(5):483-98. PubMed ID: 19419256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
